What is the impact of moderate/severe osteoarthritis on patients’ lives? Insights from a Greek cohort (PONOS study)

preprint OA: closed CC-BY-4.0
📄 Open PDF View at publisher

Abstract

Background: Osteoarthritis (OA) represents a leading cause of disability in the general population, with limited data available from the Greek OA patients. Objectives To evaluate the impact of moderate to severe symptomatic hip/knee OA that is resistant to, cannot tolerate, or is ineligible for paracetamol and/or NSAIDs and/or opioids. Methods A non-interventional, cross-sectional, prospective, epidemiological analysis of data from the medical records of patients with moderate to severe OA, recruited in a single visit from 9 sites in Greece. Outcomes included patients’ demographic and clinical characteristics, as well as patient reported outcome measures: the Hip disability and Osteoarthritis Outcome Score (HOOS), the Knee Injury and Osteoarthritis Outcome Score (KOOS) and the EuroQol-5-Dimensions 3-levels questionnaire (EQ-5D-3L). Results A total of 164 patients were included in the analysis. The majority of participants were females (78.7%), and the mean (SD) age was 70.5 (10.2) years. Presence of comorbidities was reported by 87.2% of patients, with hypertension being the most frequently reported (53.7%), followed by dyslipidemia (31.1%), obesity (24.4%) and diabetes mellitus (23.2%). Paracetamol was the most commonly used analgesic treatment (96%), followed by NSAIDs (systemic) (75%), opioids (50%) and locally applied medications (42.7%). Both hip and knee OA patients showed substantial deterioration in health related QoL and health status as reflected by the HOOS/KOOS (most impaired subscale Function in sport and recreation, followed by Hip- or Knee-related QoL), mean (SD) EQ-5D-3L index score of 0.396 (0.319) and a mean (SE) EQ-VAS score of 52.1 (1.9), respectively. Conclusion Our findings confirmed the functional disability and impaired QoL of Greek patients with moderate to severe hip/knee OA, thus emphasizing the need for appropriate intervention to reduce the overall burden of the disease both on patients and on the society.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00
unpaywall
last seen: 2026-05-22T02:00:06.705733+00:00
License: CC-BY-4.0